Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All regdanvimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis

Kee et al., Kidney Research and Clinical Practice, doi:10.23876/j.krcp.23.137
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
35th treatment shown to reduce risk in March 2022
 
*, now known with p = 0.0000009 from 7 studies, recognized in 27 countries. Efficacy is variant dependent.
Lower risk for hospitalization, progression, and recovery.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 230 hospitalized COVID-19 patients on hemodialysis, reporting lower mortality with regdanvimab treatment. The results are conflicting, with for example the text reporting HR 0.28 for regdanvimab in multivariable analysis, however Table 3 shows HR 0.95. The adjusted analysis is required because the groups are not comparable at baseline, with the control group having a much higher prevalence of severe cases.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5 Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
Kee et al., 23 Jan 2024, retrospective, South Korea, peer-reviewed, mean age 67.9, 10 authors, study period 1 December, 2020 - 30 November, 2021. Contact: km2071@hallym.or.kr, haynepark798@gmail.com.
This PaperRegdanvimabAll
Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
Youn Kyung Kee, Hayne Cho Park, Su Jin Yoon, Sungbong Yu, Eunsil Ko, Ajin Cho, Do Hyoung Kim, Jinseog Kim, Young-Ki Lee
Kidney Research and Clinical Practice, doi:10.23876/j.krcp.23.137
Background: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 , there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the effectiveness of regdanvimab on mortality in COVID-19-infected patients on hemodialysis (HD). Methods: We conducted an observational retrospective study in 230 COVID-19-infected patients on HD, of whom 77 (33.5%) were administered regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group) and 153 patients (66.5%) were not (no regdanvimab group). The primary outcome was in-hospital mortality. We compared mortality rates according to the use of regdanvimab and investigated the factors associated with mortality. Results: Fifty-nine deaths occurred during hospitalization, 49 in the no regdanvimab group (32.0%) and 10 in the regdanvimab group (13.0%), and the mortality rate was significantly higher in the no regdanvimab group than that in the regdanvimab group (p = 0.001). Multivariate Cox regression analysis showed that malignancy (p = 0.001), SPO 2 of <95% at admission (p = 0.003), and administration of antibiotics and regdanvimab (p = 0.007 and p = 0.002, respectively) were significantly associated factors with mortality. Conclusion: Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability to infection and high mortality of ESRD patients, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD.
Conflicts of interest All authors have no conflicts of interest to declare. Authors' contributions ORCID Youn Kyung Kee, https://orcid.org/0000-0002-0555-9909 Hayne Cho Park, https://orcid.org/0000-0002-1128-3750 Su Jin Yoon, https://orcid.org/0009-0008-3676-1799 Sungbong Yu, https://orcid.org/0000-0002-1989-6121 Eunsil Ko, https://orcid.org/0000-0001-5959-5545 AJin Cho, https://orcid.org//0000-0001-7097-7026 Do Hyoung Kim, https://orcid.org/0000-0002-8664-8830 Jinseog Kim, https://orcid.org/0000-0003-3172-3212 Young-Ki Lee, https://orcid.org/0000-0003-3464-6144
References
Ariës, Van Den Bergh, Beudel, Clinical course of COVID-19 in the Netherlands: an overview of 2607 patients in hospital during the first wave, Ned Tijdschr Geneeskd
Biswas, Rahaman, Biswas, Haque, Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis, Intervirology, doi:10.1159/000512592
Chae, Choi, Lim, The Effectiveness of the use of regdanvimab (CT-P59) in addition to remdesivir in patients with severe COVID-19: a single center retrospective study, Trop Med Infect Dis, doi:10.3390/tropicalmed7030051
Cheng, Luo, Wang, Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int, doi:10.1016/j.kint.2020.03.005
Chupp, Spichler-Moffarah, Søgaard, A phase 2 randomized, double-blind, placebo-controlled trial of oral camostat mesylate for early treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste, medRxiv, doi:10.1101/2022.01.28.22270035
De Meester, Bacquer, Naesens, Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study, J Am Soc Nephrol, doi:10.1681/asn.2020060875
Goicoechea, Cámara, Macías, COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain, Kidney Int, doi:10.1016/j.kint.2020.04.031
Henkens, Raafs, Verdonschot, Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study, BMC Geriatr, doi:10.21203/rs.3.rs-955049/v1
Henry, Lippi, Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Int Urol Nephrol, doi:10.1007/s11255-020-02451-9
Jang, Oh, Kim, Clinical effectiveness of regdanvimab treatment for mild-to-moderate COVID-19: a retrospective cohort study, Curr Ther Res Clin Exp, doi:10.1016/j.curtheres.2022.100675
Kato, Chmielewski, Honda, Aspects of immune 10 www.krcp-ksn.org Kidney Res Clin Pract [Epub ahead of print] dysfunction in end-stage renal disease, Clin J Am Soc Nephrol, doi:10.2215/cjn.00950208
Kim, Jang, Hong, Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection, Clin Ther, doi:10.1016/j.clinthera.2021.08.009
Kim, Ryu, Lee, A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat Commun, doi:10.1038/s41467-020-20602-5
Kuriakose, Singh, Pau, Developing treatment guidelines during a pandemic health crisis: lessons learned from COVID-19, Ann Intern Med, doi:10.7326/m21-1647
Langford, So, Raybardhan, Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.07.016
Lee, Lee, Ko, Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease, Front Immunol, doi:10.3389/fimmu.2021.772320
Ly-Cov555 Study, Group, Lundgren, Grund, A neutralizing monoclonal antibody for hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/nejmoa2033130
Park, Lee, Ko, COVID-19-related clinical outcomes among Korean hemodialysis patients, Kidney Res Clin Pract, doi:10.23876/j.krcp.22.023
Portolés, Marques, López-Sánchez, Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak, Nephrol Dial Transplant, doi:10.1093/ndt/gfaa189
Posso, Comas, Román, Comorbidities and mortality in patients with COVID-19 aged 60 years and older in a university hospital in Spain, Arch Bronconeumol (Engl Ed), doi:10.1016/j.arbres.2020.06.012
Rawson, Moore, Castro-Sanchez, COVID-19 and the potential long-term impact on antimicrobial resistance, J Antimicrob Chemother, doi:10.1093/jac/dkaa194
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med, doi:10.1007/s00134-020-05991-x
Saran, Robinson, Abbott, US renal data system 2019 annual data report: epidemiology of kidney disease in the United States, Am J Kidney Dis, doi:10.1053/j.ajkd.2019.09.003
Singh, De, Antiviral agents for the treatment of COVID-19: progress and challenges, Cell Rep Med, doi:10.1016/j.xcrm.2022.100549
Syed, Regdanvimab: first approval, Drugs, doi:10.1007/s40265-021-01626-7
Valeri, Robbins-Juarez, Stevens, Presentation and outcomes of patients with ESKD and COVID-19, J Am Soc Nephrol, doi:10.1681/asn.2020040470
Van De Veerdonk, Bourboulis, Pickkers, A guide to immunotherapy for COVID-19, Nat Med, doi:10.1038/s41591-021-01643-9
Van Duin, Barlow, Nathwani, The impact of the COVID-19 pandemic on antimicrobial resistance: a debate, JAC Antimicrob Resist, doi:10.1093/jacamr/dlaa053
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA, doi:10.1001/jama.2020.12839
Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Zuccaro, Celsa, Sambo, Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE), Sci Rep, doi:10.1038/s41598-020-80679-2
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit